Your browser doesn't support javascript.
loading
Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
Schmid, Gabriel; Notaro, Sara; Reimer, Daniel; Abdel-Azim, Samira; Duggan-Peer, Michaela; Holly, Jessica; Fiegl, Heidi; Rössler, Julia; Wiedemair, Annemarie; Concin, Nicole; Altevogt, Peter; Marth, Christian; Zeimet, Alain Gustave.
Afiliação
  • Schmid G; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. gabriel.schmid@i-med.ac.at.
  • Notaro S; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. sara.notaro@hotmail.it.
  • Reimer D; Department of Gynecology and Obstetrics, University of Brescia, Piazza Spedali Civili 1, 25123, Brescia, Italy. sara.notaro@hotmail.it.
  • Abdel-Azim S; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. daniel.reimer@i-med.ac.at.
  • Duggan-Peer M; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. Samira.Abdel-Azim@i-med.ac.at.
  • Holly J; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. michaela.peer@i-med.ac.at.
  • Fiegl H; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. jessica.holly@i-med.ac.at.
  • Rössler J; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. Heidelinde.Fiegl@i-med.ac.at.
  • Wiedemair A; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. julia.roessler@uki.at.
  • Concin N; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. annemarie.wiedemair@uki.at.
  • Altevogt P; Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. nicole.concin@i-med.ac.at.
  • Marth C; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. p.altevogt@dkfz-heidelberg.de.
  • Zeimet AG; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. p.altevogt@dkfz-heidelberg.de.
BMC Cancer ; 16: 102, 2016 Feb 15.
Article em En | MEDLINE | ID: mdl-26879132
BACKGROUND: An increasing body of evidence shows that miR-34 family has tumor suppressive properties mediating apoptosis, cell cycle arrest and senescence. In ovarian cancer, miR34 family members were found to be under expressed. Particularly miR-34a has been revealed to be a direct transcriptional target of p53 which is frequently mutated in epithelial ovarian carcinomas especially in high grade serous cancer. Moreover, methylation of miR-34a CpG Islands was found to down-regulate miR-34a expression. The aim of this study was to investigate the clinical relevance of mir34a as well as its promoter methylation in a subset of 133 ovarian cancers with a special focus on the p53 mutation status, the dualistic type I and type II ovarian cancer model and the different histotypes. METHODS: One hundred thirty-three epithelial ovarian cancers and 8 samples of healthy ovarian surface epithelium were retrospectively analysed for miR-34a expression with quantitative real-time reverse transcription PCR (qRT-PCR). Gene-specific DNA methylation was evaluated with MethyLight technique. RESULTS: Significantly lower miR-34a expression was found in ovarian cancers than in healthy ovarian epithelium (p = 0.002). The expression of miR-34a was found lower in type II than in type I cancers (p = 0.037), in p53 mutated as compared to p53 wild type cancers (p = 0.003) and in high grade compared to in low grade cancers (p = 0.028). In multivariate COX regression model low expressing miR-34a cancers exhibited a reduced PFS (p = 0.039) and OS (p = 0.018). In serous cancers low miR-34a levels showed a worse OS confirmed also in multivariate analysis (p = 0.022). miR-34a promoter methylation was found higher in type II cancers than in type I (p = 0.006). mir34a expression and promoter methylation showed an inverse correlation in cancer samples (p = 0.05). CONCLUSION: We demonstrated a clinical independent role of miR-34a in epithelial ovarian cancers. Moreover, we corroborated the correlation between miR-34a expression and its promoter methylation in a large set of ovarian cancers. The inverse association between miR-34a expression and grading, p53 mutation status and dualistic tumor type classification, together with its prognostic relevance may underline the tumor-suppressive character of miR-34a in ovarian cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Metilação de DNA / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Metilação de DNA / MicroRNAs Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article